Oncology Disruption Demands Strategic Transformation
Executive Summary
The rapidly accelerating complexity of oncology drug development demands a new way of doing business. To succeed in this new landscape, biopharma companies must transform their portfolios and partnerships, and shift toward more dynamic business and operating models and decision-making processes.
You may also be interested in...
Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize
Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.
Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize
Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.
Novartis Finds All-Important Head Of Oncology Business At Pfizer
Novartis has tempted Liz Barrett away from Pfizer to become CEO of Novartis Oncology, but the appointment of a new global drug development head at the Swiss multinational has yet to be announced.